New laboratory supports the company’s ongoing biomarker discovery and development strategy
Almac’s Diagnostics business unit has opened its CLIA registered laboratory.
The opening of the Almac CLIA laboratory supports the company’s ongoing biomarker discovery and development strategy by enabling the use of novel tests to stratify and enrich prospective clinical trials.
This ability is of key importance as Almac begins to transition the novel biomarkers that it has developed into clinical use, with the resulting potential to inform the drug development process and target therapies to responsive patients.
In addition to standard molecular tests, Almac has a pipeline of both internal clinical tests and companion diagnostic tests with pharma partners in development that will be delivered from the Almac CLIA laboratory.
‘We are very happy to announce the launch of our CLIA lab, which has been opened to meet both our needs and the needs of our pharma partners,’ said Professor Paul Harkin, president and managing director of Almac’s diagnostics business.
‘We have come to a point where the biomarkers we have discovered and assays that we have developed are being used to stratify patients, enrich clinical trials and affect patient treatment decisions.
‘As such, CLIA is a key necessity for the processing of these samples.’
Almac’s genomics laboratories have been supporting biomarker discovery projects for eight years and already operate under ISO17025 accreditation and work to the principles of GLP.